Induction of stable, mixed chimerism with major histocompatibility complex-incompatible cells after nonmyeloablative conditioning
| Group . | Donor (H-2) . | Recipient (H-2) . | Fludarabine (mg/kg) IP d − 6 to − 2 . | Cy (mg/kg) IP d − 3 . | 200 cGy TBI d − 1 . | BM cells IV d 0 . | Cy 200 mg/kg IP d 3 . | Engrafted/ total . | Mean % donor chimerism (SEM)3-150 . |
|---|---|---|---|---|---|---|---|---|---|
| Experiment 13-151 | |||||||||
| 1 | B10.BR (H-2k) | B10 (H-2b) | — | 200 | + | 107 | + | 0/5 | None detected |
| 2 | B10.BR (H-2k) | B10 (H-2b) | — | 200 | + | 2 × 107 | + | 8/10 | 78.96 (8.96) |
| 3 | B10.BR (H-2k) | B10 (H-2b) | 100 | — | + | 107 | + | 8/9 | 52.39 (13.29) |
| Experiment 23-152 | |||||||||
| 4 | BALB/c (H-2d) | B10 (H-2b) | — | — | + | 2 × 107 | + | 0/5 | None detected |
| 5 | BALB/c (H-2d) | B10 (H-2b) | 100 | — | + | 2 × 107 | − | 0/5 | None detected |
| 6 | BALB/c (H-2d) | B10 (H-2b) | 100 | — | − | 2 × 107 | + | 7/10 | 2.31 (0.9) |
| 7 | BALB/c (H-2d) | B10 (H-2b) | 100 | — | + | 2 × 107 | + | 10/10 | 75.07 (4.04) |
| 8 | BALB/c (H-2d) | B10 (H-2b) | 200 | — | + | 2 × 107 | + | 5/5 | 81.77 (3.25) |
| Experiment 33-152 | |||||||||
| 9 | B6.SJL (H-2b) | DBA/2 (H-2d) | — | 200 | + | 2 × 107 | + | 4/4 | 88.15 (9.02) |
| 10 | CB6 F1 (H-2b/d) | B6C3 F1(H-2b/k) | — | 200 | + | 2 × 107 | + | 4/4 | 67.53 (4.8) |
| 11 | AKR (H-2k) | B6D2 F1(H-2b/d) | — | 200 | + | 2 × 107 | + | 4/4 | 78.32 (6.28) |
| Group . | Donor (H-2) . | Recipient (H-2) . | Fludarabine (mg/kg) IP d − 6 to − 2 . | Cy (mg/kg) IP d − 3 . | 200 cGy TBI d − 1 . | BM cells IV d 0 . | Cy 200 mg/kg IP d 3 . | Engrafted/ total . | Mean % donor chimerism (SEM)3-150 . |
|---|---|---|---|---|---|---|---|---|---|
| Experiment 13-151 | |||||||||
| 1 | B10.BR (H-2k) | B10 (H-2b) | — | 200 | + | 107 | + | 0/5 | None detected |
| 2 | B10.BR (H-2k) | B10 (H-2b) | — | 200 | + | 2 × 107 | + | 8/10 | 78.96 (8.96) |
| 3 | B10.BR (H-2k) | B10 (H-2b) | 100 | — | + | 107 | + | 8/9 | 52.39 (13.29) |
| Experiment 23-152 | |||||||||
| 4 | BALB/c (H-2d) | B10 (H-2b) | — | — | + | 2 × 107 | + | 0/5 | None detected |
| 5 | BALB/c (H-2d) | B10 (H-2b) | 100 | — | + | 2 × 107 | − | 0/5 | None detected |
| 6 | BALB/c (H-2d) | B10 (H-2b) | 100 | — | − | 2 × 107 | + | 7/10 | 2.31 (0.9) |
| 7 | BALB/c (H-2d) | B10 (H-2b) | 100 | — | + | 2 × 107 | + | 10/10 | 75.07 (4.04) |
| 8 | BALB/c (H-2d) | B10 (H-2b) | 200 | — | + | 2 × 107 | + | 5/5 | 81.77 (3.25) |
| Experiment 33-152 | |||||||||
| 9 | B6.SJL (H-2b) | DBA/2 (H-2d) | — | 200 | + | 2 × 107 | + | 4/4 | 88.15 (9.02) |
| 10 | CB6 F1 (H-2b/d) | B6C3 F1(H-2b/k) | — | 200 | + | 2 × 107 | + | 4/4 | 67.53 (4.8) |
| 11 | AKR (H-2k) | B6D2 F1(H-2b/d) | — | 200 | + | 2 × 107 | + | 4/4 | 78.32 (6.28) |
BMT indicates bone marrow transplantation; TBI, total body irradiation; IP, intraperitoneal; BM, bone marrow; IV, intravenous; Cy, cyclophosphamide; —, not applicable.
Chimerism was measured in peripheral blood 6 months after transplantation.
Donor and recipient differ in the expression of major histocompatibility antigens.
Donor and recipient differ in the expression of major + minor histocompatibility antigens.